Skip to search formSkip to main contentSkip to account menu
Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells.
TLDR
The results of a proof-of-concept clinical trial in which patients with relapsed or refractory indolent B-cell lymphoma or mantle cell lymphoma were treated with autologous T cells genetically modified by electroporation with a vector plasmid encoding a CD20-specific chimeric T- cell receptor and neomycin resistance gene show the safety, feasibility, and potential antitumor activity of adoptive T-cell therapy using this approach.
View on PubMed
Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis.
TLDR
A subset of DHL patients may be cured, and some patients may benefit from intensive induction, and a novel risk score for DHL is developed, which divides patients into high-, intermediate-, and low-risk groups.
View on PubMed
Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support.
TLDR
High-dose radioimmunotherapy with 131I-labeled antibodies is associated with a high response rate in patients with B-cell lymphoma in whom antibody biodistribution is favorable.
View on PubMed
Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies.
TLDR
It is suggested that ligation of CD20 in vivo by anti-CD20 antibodies in the presence of FcR-expressing cells may initiate signal transduction events that induce elevation of [Ca2+]i and lead to apoptosis of malignant B cells, thereby contributing to the impressive tumor regressions observed in mouse models and clinical trials using anti- CD20 MoAbs.
View on PubMed
Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells
TLDR
Several of the signal-transduction events involved in the apoptosis of malignant B cells that transpire following ligation of CD20 by anti-CD20 antibodies in the presence of Fc-receptor-expressing cells or secondary goat anti-(mouse Ig) antibodies are identified and which may contribute to the tumor regressions observed in mouse models and clinical trials.
View on Springer
Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies.
Seven murine monoclonal antibodies (MoAbs) recognizing differentiation antigens present on B-lymphocytes were analyzed in preclinical studies for their potential use for antibody-targeted therapy of…
View on PubMed
Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas.
TLDR
A single course of iodine I 131 tositumomab was significantly more efficacious than the LQC received by extensively pretreated patients with chemotherapy-refractory, low-grade, or transformed low- grade non-Hodgkin's lymphoma and had an acceptable safety profile.
View on PubMed
Evaluation and management of chylous ascites.
TLDR
Aggressive diagnostic and therapeutic interventions are not warranted in childhood cases of chylous ascites until conservative management has failed; neoplasia is rarely implicated and many cases resolve within a few months.
View on PubMed
NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas.
View on PubMed
Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase…
View on PubMed
...
...
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License